BRPI0815975B8 - preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa - Google Patents
preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosaInfo
- Publication number
- BRPI0815975B8 BRPI0815975B8 BRPI0815975A BRPI0815975A BRPI0815975B8 BR PI0815975 B8 BRPI0815975 B8 BR PI0815975B8 BR PI0815975 A BRPI0815975 A BR PI0815975A BR PI0815975 A BRPI0815975 A BR PI0815975A BR PI0815975 B8 BRPI0815975 B8 BR PI0815975B8
- Authority
- BR
- Brazil
- Prior art keywords
- aqueous preparation
- composition
- preparing
- salts
- pharmaceutical container
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 7
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 239000001384 succinic acid Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07115047.8 | 2007-08-27 | ||
| EP07115047 | 2007-08-27 | ||
| PCT/EP2008/061232 WO2009027437A1 (en) | 2007-08-27 | 2008-08-27 | Liquid formulation of g-csf conjugate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0815975A2 BRPI0815975A2 (pt) | 2015-02-18 |
| BRPI0815975B1 BRPI0815975B1 (pt) | 2019-04-02 |
| BRPI0815975B8 true BRPI0815975B8 (pt) | 2021-05-25 |
Family
ID=39862881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0815975A BRPI0815975B8 (pt) | 2007-08-27 | 2008-08-27 | preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa |
Country Status (24)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011207915B2 (en) * | 2010-01-19 | 2013-07-11 | Hanmi Science Co., Ltd. | Liquid formulations for long-acting G-CSF conjugate |
| MX2012010661A (es) | 2010-03-17 | 2013-03-25 | Biogenerix Gmbh | Metodo para obtener factor estimulante de colonias de granulocitos (g-csf) humano recombinante biologicamente activo. |
| EP2384759A1 (en) | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
| TWI751154B (zh) * | 2016-04-18 | 2022-01-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種重組人粒細胞集落刺激因子的製備方法 |
| IT201700108526A1 (it) * | 2017-09-28 | 2019-03-28 | Alfasigma Spa | Composizioni orali per il trattamento del refluso gastroesofageo. |
| CN112312890A (zh) * | 2018-05-04 | 2021-02-02 | 伊尔科根医药工业和贸易有限公司 | 稳定的杂合fc融合g-csf制剂 |
| CN114224853B (zh) * | 2022-01-04 | 2022-09-23 | 山东新时代药业有限公司 | 聚乙二醇化重组人粒细胞刺激因子注射用冻干制剂 |
| TW202417034A (zh) * | 2022-08-19 | 2024-05-01 | 大陸商億一生物醫藥開發（上海）有限公司 | 包含ｇ—ｃｓｆ之調配物及其用途 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| CH596313A5 (cg-RX-API-DMAC7.html) | 1975-05-30 | 1978-03-15 | Battelle Memorial Institute | |
| US4414147A (en) | 1981-04-17 | 1983-11-08 | Massachusetts Institute Of Technology | Methods of decreasing the hydrophobicity of fibroblast and other interferons |
| US5675941A (en) | 1983-12-09 | 1997-10-14 | Dykmans; Maximiliaan J. | Method and apparatus for constructing prestressed structures utilizing a membrane and floating dome assembly |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
| NZ229098A (en) | 1988-05-13 | 1992-10-28 | Amgen Inc | (bg-csf) bovine granulocyte colony stimulating factor, recombinant methods and pharmaceuticals |
| US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
| US6166183A (en) | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
| US5399345A (en) | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
| DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| EP0648239A4 (en) | 1992-07-02 | 1995-09-27 | Collagen Corp | BIOCOMPATIBLE POLYMERIC CONJUGATES. |
| WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5874075A (en) | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
| EP1090645B1 (en) | 1994-02-08 | 2005-12-07 | Amgen Inc., | Oral delivery of chemically modified proteins |
| DK0744409T3 (da) | 1994-02-23 | 2008-11-10 | Kyowa Hakko Kogyo Kk | Accelerator for vækst af blodplader |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| CA2242488A1 (en) | 1996-02-15 | 1997-08-21 | Novo Nordisk A/S | Conjugation of polypeptides |
| ATE263841T1 (de) | 1997-01-16 | 2004-04-15 | Neose Technologies Inc | Praktische in vitro sialylierung von rekombinanten glykpproteinen |
| KR100565022B1 (ko) | 1997-06-06 | 2006-03-30 | 교와 핫꼬 고교 가부시끼가이샤 | 화학적으로 개질된 폴리펩타이드 |
| US7306931B2 (en) | 2000-05-16 | 2007-12-11 | Bolder Biotechnology, Inc. | Method for refolding proteins containing free cysteine residues |
| US6540672B1 (en) * | 1998-12-09 | 2003-04-01 | Novo Nordisk A/S | Medical system and a method of controlling the system for use by a patient for medical self treatment |
| FR2796071B1 (fr) | 1999-07-08 | 2001-09-07 | Hoechst Marion Roussel Inc | Procede de purification de facteur de stimulation de colonies de granulocytes |
| US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| WO2001051510A2 (en) | 2000-01-10 | 2001-07-19 | Maxygen Holdings Ltd | G-csf conjugates |
| EP1260230A4 (en) | 2000-02-29 | 2008-08-06 | Chugai Pharmaceutical Co Ltd | LONG-TERM STABILIZED PREPARATIONS |
| CA2407707A1 (en) | 2000-05-12 | 2001-11-22 | Neose Technologies, Inc. | In vitro fucosylation recombinant glycopeptides |
| CA2408685C (en) | 2000-05-15 | 2011-02-01 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivate |
| KR100396983B1 (ko) | 2000-07-29 | 2003-09-02 | 이강춘 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
| EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
| US7998929B2 (en) * | 2000-09-01 | 2011-08-16 | Chugai Seikyaku Kabushiki Kaisha | Solution preparations stabilized over long time |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| DK2322229T3 (en) | 2001-10-10 | 2017-03-27 | Novo Nordisk As | Remodeling and Glycoconjugation of Factor IX |
| SI21102A (sl) | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| SI21273A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina |
| EP1660134B1 (en) | 2003-08-08 | 2010-12-29 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and g-csf |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| DE10348550A1 (de) * | 2003-10-20 | 2005-06-16 | Hexal Biotech Forschungsgmbh | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| EP1682184B1 (en) | 2003-11-04 | 2013-10-16 | LEK Pharmaceuticals d.d. | Stable pharmaceutical composition comprising granulocyte-colony stimulating factor |
| NZ547554A (en) | 2003-12-03 | 2009-09-25 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| ES2560657T3 (es) * | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | Glicosilación con unión en O de péptidos G-CSF |
| CN102302787A (zh) | 2004-03-11 | 2012-01-04 | 费森尤斯卡比德国有限公司 | 羟烷基淀粉和蛋白质的接合物 |
| BRPI0508607A (pt) | 2004-03-11 | 2007-07-31 | Fresenius Kabi De Gmbh | conjugados de amido de hidroxialquila e uma proteìna, preparados pela aminação redutiva |
| DE102004036909B4 (de) | 2004-07-29 | 2007-04-05 | Infineon Technologies Ag | Halbleiterbasisbauteil mit Verdrahtungssubstrat und Zwischenverdrahtungsplatte für einen Halbleiterbauteilstapel sowie Verfahren zu deren Herstellung |
| NZ556436A (en) * | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
| WO2006097944A2 (en) | 2005-03-17 | 2006-09-21 | Zenotech Laboratories Limited | Process for the purification of recombinant granulocyte-colony stimulating factor |
| EP1888119B1 (en) * | 2005-06-01 | 2011-03-09 | Maxygen, Inc. | Pegylated g-csf polypeptides and methods of producing same |
| EP1762250A1 (en) | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
| DE202006020194U1 (de) | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
| ITMI20061624A1 (it) | 2006-08-11 | 2008-02-12 | Bioker Srl | Mono-coniugati sito-specifici di g-csf |
| US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
| US8207112B2 (en) * | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
-
2008
- 2008-08-27 KR KR1020107004576A patent/KR20100052501A/ko not_active Ceased
- 2008-08-27 SI SI200831235T patent/SI2197919T1/sl unknown
- 2008-08-27 EP EP08787525.8A patent/EP2197919B1/en active Active
- 2008-08-27 DE DE202008017456U patent/DE202008017456U1/de not_active Expired - Lifetime
- 2008-08-27 EP EP12194213.0A patent/EP2578235A3/en not_active Withdrawn
- 2008-08-27 DK DK08787525.8T patent/DK2197919T3/da active
- 2008-08-27 BR BRPI0815975A patent/BRPI0815975B8/pt not_active IP Right Cessation
- 2008-08-27 PT PT87875258T patent/PT2197919E/pt unknown
- 2008-08-27 WO PCT/EP2008/061232 patent/WO2009027437A1/en not_active Ceased
- 2008-08-27 CN CN200880104971A patent/CN101827864A/zh active Pending
- 2008-08-27 CN CN201510065114.9A patent/CN104689333B/zh not_active Expired - Fee Related
- 2008-08-27 ES ES08787525.8T patent/ES2476915T3/es active Active
- 2008-08-27 UA UAA201003493A patent/UA98001C2/uk unknown
- 2008-08-27 AU AU2008292186A patent/AU2008292186B9/en active Active
- 2008-08-27 HR HRP20140590AT patent/HRP20140590T1/hr unknown
- 2008-08-27 RS RS20140361A patent/RS53404B/sr unknown
- 2008-08-27 CA CA2696594A patent/CA2696594C/en not_active Expired - Fee Related
- 2008-08-27 NZ NZ583276A patent/NZ583276A/en not_active IP Right Cessation
- 2008-08-27 US US12/675,749 patent/US8546328B2/en active Active
- 2008-08-27 MX MX2010002448A patent/MX2010002448A/es unknown
- 2008-08-27 PL PL08787525T patent/PL2197919T3/pl unknown
- 2008-08-27 JP JP2010522361A patent/JP5570988B2/ja not_active Expired - Fee Related
- 2008-08-27 EA EA201070315A patent/EA020069B1/ru not_active IP Right Cessation
-
2010
- 2010-02-03 ZA ZA201000798A patent/ZA201000798B/xx unknown
- 2010-02-25 IL IL204190A patent/IL204190A/en active IP Right Grant
-
2013
- 2013-11-05 JP JP2013229688A patent/JP5836351B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-03 CY CY20141100501T patent/CY1115908T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0815975B8 (pt) | preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa | |
| JP6152202B2 (ja) | ジフェンヒドラミン又はその塩並びにアスコルビン酸又はその塩を含有する外用組成物の変色抑制方法 | |
| BR112014027116A2 (pt) | formulação de anticorpo | |
| BRPI0908887B8 (pt) | composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica | |
| US20170202877A1 (en) | Hypochlorite formulations for wound healing | |
| BR112014009022A2 (pt) | formulações de etanercepte estabilizadas com combinações de açúcares e polióis | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| RU2011101713A (ru) | Фармацевтическая композиция | |
| BRPI0607574A2 (pt) | composição farmacêutica aerossol | |
| BRPI0412059A (pt) | método para a preparação de formulação de liberação controlada | |
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| BR112014016472A2 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
| JP2017514924A5 (cg-RX-API-DMAC7.html) | ||
| EP3058945B1 (en) | Pharmaceutical compositions and formulations for topical application with astringent and antimicrobial effect | |
| MXPA02000849A (es) | Composicion oftalmica que comprende cetotifeno. | |
| JP2018532806A5 (cg-RX-API-DMAC7.html) | ||
| CO2017009400A2 (es) | Formulación estable para administración parenteral de tapentadol | |
| BR112015024348A2 (pt) | composições farmacêuticas de tansulosina ou sais destas | |
| JP2015516943A (ja) | ポリペプチド及びその使用 | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BR112014027213A8 (pt) | nova composição de alfentanil para o tratamento de dor aguda | |
| BR0214487A (pt) | Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes | |
| ES2971823T3 (es) | Mejora de las acciones antibacterianas de un antibiótico depsipeptídico mediante cantidades sinérgicas de ácido bórico | |
| CA3188980A1 (en) | Phytonadione compositions | |
| BRPI0414968A (pt) | preparação de infusão contendo ácido (2r)-2-propiloctanóico como o ingrediente ativo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/60 (2017.01), A61P 7/06 (2006.01), A61P 25 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 17/08 (2006.01), A61P 7/06 (2006.01), A61P 25 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25D | Requested change of name of applicant approved |
Owner name: BIOGENERIX GMBH (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: RATIOPHARM GMBH (DE) |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/08/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |